Cequr Raises $115 Million Series C5 Financing To Support Commercialization And Scale-Up Of Automated Manufacturing For Cequr Simplicity Wearable Insulin-Delivery Device
Cequr Raises $115 Million Series C5 Financing To Support Commercialization And Scale-Up Of Automated Manufacturing For Cequr Simplicity Wearable Insulin-Delivery Device
04/13/21, 4:01 PM
Location
lucerneMoney raised
$115 million
Round Type
series c
CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing. The company will use the funds to advance commercial plans for CeQur SimplicityTM, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.
Company Info
Location
lucerne, colorado, united states
Additional Info
CeQur is commercializing advanced, simple-to-use insulin-delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease. The Company’s simple, three-day, wearable devices provide freedom from multiple daily insulin injections. More information can be found at www.cequr.com.